Phase II study of nab-paclitaxel for pretreated NSCLC

Phase II study of nab-paclitaxel for pretreated NSCLC - nab-paclitaxel for pretreated NSCLC

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000014357

Enrollment

Registered

2014-07-01

Start date

2014-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-small cell lung cancer

Interventions

nab-paclitaxel monotherapy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Diagnosed for NSCLC histologically. Stage IIIb or IV Age, over 20 years old. ECOG PS: 0-2 Main organ functions are maintained.

Exclusion criteria

Exclusion criteria: Hypersensitivity for drugs and albumin. patient with grade 2 of peripheral neuropathy. Patient with severe infection. Patient with Patient with SVC. Patient with uncontroled diabetes mellitus, angina,heart disease and gastrointestinal ulceration.

Design outcomes

Primary

Measure	Time frame
Response rate	—

Secondary

Measure	Time frame
PFS,OS, safty	—

Countries

Japan

Contacts

Public ContactSatoshi Igawa

Kitasato university hospital Respiratory medicine

igawa@kitasato-u.ac.jp042-777-8111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026